Jiangsu Vcare Completes Pre-IND Submission for VC005, a Highly Selective JAK1 Inhibitor New Drug
Published Time:
2021-03-12 17:39
Source:
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) successfully submitted a Pre-IND application to the NMPA for its VC005 tablets. VC005 is a highly selective JAK1 inhibitor independently designed by Jiangsu Vcare. It is intended for the clinical treatment of inflammatory bowel disease (IBD), an intestinal autoimmune disorder.
IBD encompasses chronic, non-specific inflammatory conditions of the gut, primarily ulcerative colitis (UC) and Crohn's disease (CD). Clinical manifestations include diarrhea, abdominal pain, and even bloody stools. UC can occur at any age, with peaks between 15-30 and 50-70 years old. It primarily affects the rectum and sigmoid colon, exhibiting diffuse distribution. CD can also occur at any age but is most common in adolescence. Lesions can affect the entire gastrointestinal tract from mouth to anus, characterized by segmental and skip lesions, most frequently involving the terminal ileum, colon, or both the small and large intestine. Both UC and CD are chronic inflammatory diseases currently without a cure, requiring lifelong medication management. Often termed "incurable intestinal disorders," they carry high relapse rates of 70–90%. The incidence of IBD in China is steadily increasing, establishing it as a common and challenging condition within the digestive system. It represents a key focus and significant challenge in both basic research and clinical diagnosis/treatment of digestive diseases.
Janus kinases (JAKs) comprise a family of tyrosine kinases, consisting of four members: JAK1, JAK2, and TYK2. JAKs play crucial roles in signal transduction for numerous cytokines. Together with their downstream effectors, Signal Transducers and Activators of Transcription (STATs), they mediate cytokine receptor regulation of nuclear gene transcription and expression. Dysfunction of the JAK-STAT signaling pathway is closely associated with the pathogenesis of hematological diseases such as polycythemia vera, thrombocythemia, leukemia, and myelofibrosis, as well as autoimmune disorders including rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), IBD, and atopic dermatitis. Consequently, the JAK kinase family has emerged as a critical therapeutic target for these conditions.
About VC005
VC005 is a novel, potent, gut-restricted selective JAK1 inhibitor independently developed by Jiangsu Vcare. It features controllable systemic exposure coupled with high intestinal exposure. Preclinical studies have demonstrated that VC005 exhibits a low effective dose, high tolerated dose, and minimal side effects in animal models, offering dual advantages of safety and efficacy. It holds promise as a potential globally leading gut-selective anti-inflammatory drug.
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn